Form 4: Rapport Therapeutics Director Paul Silva Granted Stock Options

Rapport Therapeutics, Inc. Director Paul M. Silva was granted 10,925 stock options with an exercise price of $10.95, aligning his interests with shareholders.

Summary

• Paul M. Silva, a Director of Rapport Therapeutics, Inc. (RAPP), was granted 10,925 stock options.
• The transaction date for this grant was June 17, 2025.
• Each stock option has an exercise price of $10.95.
• The options were acquired at a price of $0 per derivative security, which is typical for compensation grants.
• The shares underlying these options will vest upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, contingent on Mr. Silva's continued service.
• The options have an expiration date of June 17, 2035.
• Following this transaction, Mr. Silva beneficially owns 10,925 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options to a director aligns their interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event and not a major catalyst.

Positives

• The grant of stock options to Director Paul M. Silva aligns his financial interests with those of the company's shareholders, incentivizing long-term performance.

Future Outlook

The document does not contain specific forward-looking statements or guidance beyond the vesting schedule of the granted options.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice across industries to incentivize leadership and align their interests with company performance. It does not provide broader industry trends or competitive insights.

Related Party Transactions

• The grant of 10,925 stock options to Paul M. Silva, a Director of Rapport Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance.
• Director (Paul M. Silva): Receives equity compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The stock options will vest upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, subject to the director's continued service.
• Upon vesting, the director will have the right to exercise the options at $10.95 per share until the expiration date of June 17, 2035.

Key Dates

Keywords

Rapport Therapeutics, RAPP, Stock Options, Insider Transaction, SEC Form 4, Director Compensation, Equity Grant, Paul M. Silva